Regeneron Pharmaceuticals (REGN) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Royalty Pharma (RPRX) has outperformed Regeneron Pharmaceuticals (REGN) over the past year, gaining 57.2% versus a gain of 27.2%. Over five years, RPRX leads with a +47.9% price change compared with +34.1% for REGN. Regeneron Pharmaceuticals is the larger company by market cap ($76.40 billion vs $32.80 billion), about 2.3 times the size, while Royalty Pharma is growing revenue faster (+5.1% vs +1.0%).
On valuation, Royalty Pharma trades at a lower forward P/E (9.9x vs 12.1x for Regeneron Pharmaceuticals). Royalty Pharma offers the higher dividend yield (1.60% vs 0.49%). Royalty Pharma converts more of its revenue into profit, with a net margin of 32.4% versus 31.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | REGN | RPRX |
|---|---|---|
| Share price | $742.12 | $56.76 |
| Market cap | $76.40B | $32.80B |
| 1-day change | +0.46% | +0.57% |
| YTD return | -3.85% | +46.89% |
| 1-year return | +27.24% | +57.23% |
| 5-year return | +34.14% | +47.85% |
| P/E ratio (TTM) | 18.27 | 30.19 |
| Forward P/E | 12.07 | 9.90 |
| EPS (TTM) | $40.63 | $1.88 |
| Dividend yield | 0.49% | 1.60% |
| Annual dividend | $3.64 | $0.91 |
| Revenue (latest FY) | $14.34B | $2.38B |
| Revenue growth (YoY) | +0.99% | +5.06% |
| Net income (latest FY) | $4.50B | $770.95M |
| Operating margin | 24.95% | 65.58% |
| Net margin | 31.41% | 32.42% |
| 52-week high | $859.34 | $64.38 |
| 52-week low | $541.00 | $35.23 |
| Distance from 52-week high | -13.64% | -11.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +15.38% | +15.19% |
| Average volume | 741.47K | 2.92M |
| Shares outstanding | 101.14M | 445.28M |
| Employees | 15,410 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Regeneron Pharmaceuticals is about 2.3 times larger than Royalty Pharma by market value ($76.40B vs $32.80B).
- RPRX has outperformed REGN by 30.0 percentage points over the past year.
- Royalty Pharma trades at a higher earnings multiple (30.2x vs 18.3x trailing P/E).
- Royalty Pharma offers a meaningfully higher dividend yield (1.60% vs 0.49%).
About Regeneron Pharmaceuticals
REGN stock →Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 15,410 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
REGN vs RPRX FAQ
Which is bigger, Regeneron Pharmaceuticals or Royalty Pharma?
Regeneron Pharmaceuticals (REGN) is larger, with a market capitalization of $76.40B compared with $32.80B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, REGN or RPRX?
RPRX returned +57.23% over the past 12 months, compared with +27.24% for REGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, REGN or RPRX?
REGN has the lower trailing P/E at 18.3, versus 30.2 for RPRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Regeneron Pharmaceuticals or Royalty Pharma?
Royalty Pharma has the higher yield at 1.60%, compared with 0.49% for Regeneron Pharmaceuticals.
Are Regeneron Pharmaceuticals and Royalty Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.